Compare DexCom, Inc. (DXCM) vs Vanguard Growth Index Fund ETF (VUG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Vanguard Growth Index Fund ETF — how do they compare? DexCom, Inc. trades at $77.18 (market cap $28.06B), while Vanguard Growth Index Fund ETF trades at $86.38. The key difference: Vanguard Growth Index Fund ETF is trading nearer its 52-week high, DexCom, Inc. nearer its low. Which is the better fit depends on your goals.
| DXCM | VUG | |
|---|---|---|
Market Cap | $28.06B | — |
Sector | Health | Sector/Thematic |
52-Week High | $89.53 | $90.29 |
52-Week Low | $54.84 | $70.00 |
Enterprise Value | $27.03B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.
The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.
VUG trades at $86.75, down 0.24% on the day, with a bullish technical outlook supported by moving averages. The ETF's low expense ratio of 0.03% and strong historical performance, including a 411% total return over the past decade, highlight its appeal. Recent news emphasizes its growth focus, with 70% allocation to tech stocks, and a 1:6 stock split executed in April 2026 enhances accessibility.
Outlook remains positive due to cost efficiency and tech exposure, but risks include concentration in growth stocks and market volatility. Analyst sentiment is favorable, citing long-term wealth-building potential, though investors should monitor sector rotations and economic shifts that could impact performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Vanguard Growth Index Fund ETF
VUG is an index-based ETF that tracks the CRSP US Large Cap Growth Index, providing concentrated exposure to the largest and fastest-growing companies in the United States. It focuses on stocks with high growth potential across tech, communication, and consumer sectors, serving as a low-cost, high-conviction core holding for long-term capital appreciation.
Read more on VUG →
